AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company focused on developing proprietary botulinum toxin complex therapeutics for a range of therapeutic indications. The company became publicly traded through its merger with Priveterra Acquisition Corp, a blank-check company sponsored by Priveterra Sponsor LLC that completed its IPO in 2021. AEON filed its quarterly report on Form 10-Q with the SEC on May 17, 2023, under accession number 0001104659-23-061821, reflecting its post-merger status as a reporting company operating in the biotechnology and specialty pharmaceuticals sector. For complete SPAC transaction history, filing timelines, and deal metrics on AEON Biopharma and hundreds of other SPAC companies, sign up for full data access at SpacDesk.